Core Insights - Inhibrx Biosciences, Inc. announced positive primary results from the ChonDRAgon clinical trial (n=206) evaluating ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma compared to placebo [1] - Based on these results, Inhibrx plans to submit a marketing application for ozekibart for chondrosarcoma to U.S. regulatory authorities by the end of June 2026 [1] - Ozekibart is the first investigational drug to significantly improve progression-free survival (PFS) in chondrosarcoma patients in a randomized controlled trial, addressing a significant unmet medical need [1] Group 1 - Inhibrx holds exclusive development and commercialization rights for ozekibart in mainland China, Hong Kong, Macau, and Taiwan through a licensing agreement with its wholly-owned subsidiary, HJB [1] - The encouraging clinical data further confirms the value of ozekibart for global patients and in regions where the company has exclusive rights [1] Group 2 - In addition to the registration trial, Inhibrx is advancing an expanded cohort study to evaluate ozekibart in combination with irinotecan for the treatment of Ewing sarcoma and colorectal cancer [2] - Early results show promising signals, supporting further exploration of ozekibart's potential in these difficult-to-treat tumors with unmet medical needs [2]
创胜集团-B合作伙伴Inhibrx公布ozekibart治疗软骨肉瘤的 II期临床试验积极结果，计划于2026年递交BLA的业绩进展